Journal of Neuro-Oncology

, Volume 81, Issue 3, pp 279–285 | Cite as

Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine

  • Anna Maria MauroEmail author
  • Chiara Bomprezzi
  • Simonetta Morresi
  • Leandro Provinciali
  • Francesco Formica
  • Maurizio Iacoangeli
  • Massimo Scerrati
Clinical – Patient Studies


Early postoperative seizures are defined as those that appear within the first week after surgery and are a well-known and feared complication in patients with supratentorial brain tumors. Few studies have investigated the value of pharmacological prophylaxis in the prevention of postoperative seizures in these patients and their outcome has not been consistent. Furthermore, the efficacy of the new generation of antiepileptic agents in the prophylaxis of perioperative seizures has not been assessed so far. We analyzed the data related to 150 patients harboring supratentorial brain gliomas with the aim to assess the efficacy of oxcarbazepine in preventing the occurrence or the recurrence of early postoperative seizures and its tolerability when it is rapidly titrated. Only four patients (2.7%) experienced seizures within the first week after surgery. Patients did not report disturbances during the titration phase. Regarding adverse events in the first week, six patients (4%) showed minor skin rash. Persistent symptomatic hyponatremia never occurred. Our data showed that oxcarbazepine can be a good alternative to traditional antiepileptic agents in the prevention of perioperative seizures being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors. Moreover, oxcarbazepine can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low hematological side effects.


Antiepileptic drugs Brain tumors Early seizures Oxcarbazepine Surgery 


  1. 1.
    Foy PM, Copeland GP, Shaw MDM (1981) The natural history of postoperative seizures. Acta Neurochir 57:15–22CrossRefGoogle Scholar
  2. 2.
    Foy PM, Chadwick DW, Rajgopalan N, Johnson AL, Shaw MD (1992) Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy? J Neurol Neurosurg Psychiatry 55:753–757PubMedGoogle Scholar
  3. 3.
    DeSantis A, Villani R, Sinisi M, Stocchetti N, Perucca E (2002) Add-on Phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 43(2):175–182CrossRefGoogle Scholar
  4. 4.
    Beenem LFM, Lindeboom J, Kasteleijn-Nolst Trenitè DGA, Heimans JJ, Snoek FJ, Touw DJ, Adèr HJ, van Alphen HAM (1999) Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J Neurol Neurosurg Psychiatry 67:474–480CrossRefGoogle Scholar
  5. 5.
    Matthew E, Sherwin AL, Welner SA, Odusote K, Stratford JG (1980) Seizures following intracranial surgery: incidence in the first post-operative week. Can J Neurol Sci 7:285–290PubMedGoogle Scholar
  6. 6.
    Kuijlen JM, Teernstra OP, Kessels AG, Herpers MJ, Beuls EA (1996) Effectiveness of antiepileptic drug prophylaxis used in supratentorial craniotomies. A meta-analysis. Seizure 5:291–298PubMedCrossRefGoogle Scholar
  7. 7.
    DeSantis A (1991) Diffusion of antiepileptic prophylaxis in Italy. In: Murri L, Parenti G, Annegers JF (eds) Pharmacological prophylaxis of posttraumatic epilepsy. Piccin Edizioni, Padua, pp 95–112Google Scholar
  8. 8.
    Perucca E (1996) Priciples of drug treatment. In: Shorvon SD, Dreifuss F, Fish D (eds) The treatment of epilepsy. Blackwell Science, Oxford, pp 162–168Google Scholar
  9. 9.
    Glantz M, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 54:1886–1893PubMedGoogle Scholar
  10. 10.
    Lee ST, Lui TN, Chang CN, Cheng WC, Wang DJ, Heimburger RF, Lin CG (1989) Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 31:361–364PubMedCrossRefGoogle Scholar
  11. 11.
    Kvuam DA, Loftus CM, Copeland B, Quest DO (1983) Seizures during the immediate postoperative period. Neurosurgery 12(1):14–17CrossRefGoogle Scholar
  12. 12.
    North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB (1983) Phenytoin and post-operative epilepsy: a double-blind study. J Neurosurg 58:672–677PubMedGoogle Scholar
  13. 13.
    Temkin NR (2002) Prophylactic anticonvulsants after neurosurgery. Epilepsy Curr 2(4):105–107PubMedCrossRefGoogle Scholar
  14. 14.
    Franceschetti S, Binelli S, Casazza M, Lodrini S, Panzica F, Plachino F, Solero CL, Avanzini G (1990) Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumors. Acta Neurochir 103:47–51CrossRefGoogle Scholar
  15. 15.
    Forsyth PA, Weaver S, Fulton D, Brasher PM, Sutherland G, Stewart D, Hagen NA, Barnes P, Cairncross JG, DeAngelis LM (2003) Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30:106–112PubMedGoogle Scholar
  16. 16.
    Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis S (1996) A randomised, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46(4):985–991PubMedGoogle Scholar
  17. 17.
    Boarini DJ, Beck DW, VanGilder JC (1985) Postoperative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 16:290–292PubMedCrossRefGoogle Scholar
  18. 18.
    Levati A, Savoia G, Zoppi F, Boselli L, Tommasino C (1996) Peri-operative prophylaxis with phenitoin: dosage and therapeutic plasma levels. Acta Neurochir 138:274–278CrossRefGoogle Scholar
  19. 19.
    Temkin NR (2001) Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42:515–524PubMedCrossRefGoogle Scholar
  20. 20.
    Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS (2004) Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 79:1489–1494PubMedCrossRefGoogle Scholar
  21. 21.
    Schachter SC (1999) Oxcarbazepine: current status and clinical applications. Exp Opin Invest Drugs 8(7):1103–1112CrossRefGoogle Scholar
  22. 22.
    Schmidt D, Sachdeo R (2000) Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 1:396–405PubMedCrossRefGoogle Scholar
  23. 23.
    Wellington K, Goa KL (2001) Oxcarbazepine: an update of its efficacy in management of epilepsy. CNS Drugs 15(2):137–163PubMedCrossRefGoogle Scholar
  24. 24.
    Kleihues P, Cavanee WK (eds) (2000) World Health Organization classification of tumors. Pathology and genetics: tumors of the Nervous system. IARC press, LyonGoogle Scholar
  25. 25.
    Reynolds EH (1983) Early treatment and prognosis of epilepsy. Epilepsia 28:97–106Google Scholar
  26. 26.
    Vecht CJ, Wagner GL, Wilms EB (2003) Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents. Sem Oncol 30(6 suppl 19):49–52CrossRefGoogle Scholar
  27. 27.
    Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404–409PubMedCrossRefGoogle Scholar
  28. 28.
    Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255–260PubMedCrossRefGoogle Scholar
  29. 29.
    Beydoun A, Kutluay E (2001) Oxcarbazepine. Expert Opin Pharmacother 3(1):59–71CrossRefGoogle Scholar
  30. 30.
    Tecoma ES (1999) Oxcarbazepine. Epilepsia 40(suppl 5):S37-S46PubMedCrossRefGoogle Scholar
  31. 31.
    Grant SM, Faulds D (1992) Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 43:873–888PubMedGoogle Scholar
  32. 32.
    Lloyd P, Flesch G, Dieterle W (1994) Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35(suppl 3):S10–S13PubMedGoogle Scholar
  33. 33.
    Perucca E (1999) The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 40(suppl 9):S7–S13PubMedCrossRefGoogle Scholar
  34. 34.
    Schutz H, Feldman KF, Faigle JW, Kriemler HP, Winkler T (1986) The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16:769–778PubMedCrossRefGoogle Scholar
  35. 35.
    Jung H, Noguez A, Mayet L, Fuentes I, Gonzales-Esquivel DF (1997) The distribution of 10-hydroxycarbazepine in blood compartments. Biopharm Drug Disposit 18:17–23CrossRefGoogle Scholar
  36. 36.
    Gonzalez-Esquivel DF, Ortega-Gavilan M, Alcantara-Lopez G, Jung-Cook H (2000) Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res 31(2):202–205PubMedCrossRefGoogle Scholar
  37. 37.
    Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR (1990) A randomised, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 323:497–502PubMedCrossRefGoogle Scholar
  38. 38.
    Baruzzi A, Albani F, Riva R (1994) Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35(suppl 3):S14–S19PubMedGoogle Scholar
  39. 39.
    Larkin JG, Mckee PJ, Forrest G, Beastall GH, Park BK, Lowrie JI, Lloyd P, Brodie MJ (1991) Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 31:65–71PubMedGoogle Scholar
  40. 40.
    Sachdeo RC, Wasserstein A, Mesenbrik PJ, D’Souza J (2002) Effect of oxcarbazepine on sodium concentration and water handling. Ann Neurol 51:613–620PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Anna Maria Mauro
    • 1
    Email author
  • Chiara Bomprezzi
    • 1
  • Simonetta Morresi
    • 1
  • Leandro Provinciali
    • 1
  • Francesco Formica
    • 2
  • Maurizio Iacoangeli
    • 2
  • Massimo Scerrati
    • 2
  1. 1.Neurology Unit, Department of Neurological and Motor SciencePolytechnic University of MarcheAnconaItaly
  2. 2.Neurosurgery Unit, Department of Neurological and Motor SciencePolytechnic University of MarcheAnconaItaly

Personalised recommendations